ArticlePharmaceutics2022
Integrated Analysis of Metabolomics and Lipidomics in Plasma of T2DM Patients with Diabetic Retinopathy.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Integrating mass spectrometry imaging and data-driven segmentation for spatial metabolic mapping of diabetic eye disease.Journal of pharmaceutical analysis · 2026Article
- [Establishment and application of a knowledge-directed pseudo-targeted analytical method for diabetic retinopathy].Se pu = Chinese journal of chromatography · 2026Article
- Analysis of Chemical Constituents of Jiaotai Pill Based on UPLC-Q-Exactive Orbitrap-HRMS Technology and Its Antidiabetic Type 2 Mechanism in Network Pharmacology.Current pharmaceutical design · 2026Article
- Article
- Novel High-Resolution Lipidomes Could Serve as New Biomarkers for Diabetic Retinopathy: A Bidirectional and Mediated Mendelian Randomization Study.Journal of cellular and molecular medicine · 2025Article
- Causal role of plasma liposome in diabetic retinopathy: mendelian randomization (MR) study.Diabetology & metabolic syndrome · 2025Article
- New insights of potential biomarkers in diabetic retinopathy: integrated multi-omic analyses.Frontiers in endocrinology · 2025Review
- Identification of genes related to fatty acid metabolism in type 2 diabetes mellitus.Biochemistry and biophysics reports · 2024Article
- Comparative Proteomic Analysis of Type 2 Diabetic versus Non-Diabetic Vitreous Fluids.Life (Basel, Switzerland) · 2024Article
- Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus.Cardiovascular diabetology · 2024Article
- Relationship between circulating metabolites and diabetic retinopathy: a two-sample Mendelian randomization analysis.Scientific reports · 2024Article
- Recent Advances and Perspectives in Relation to the Metabolomics-Based Study of Diabetic Retinopathy.Metabolites · 2023Review
- Untargeted Multiomics Approach Coupling Lipidomics and Metabolomics Profiling Reveals New Insights in Diabetic Retinopathy.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Diabetic retinopathy (DR) is a major cause of blindness worldwide and may be non-proliferative (NPDR) or proliferative (PDR). To Investig.gate the metabolomic and lipidomic characteristics of plasma in DR patients, plasma samples were collected from patients with type 2 diabetes mellitus (DR group) with PDR (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.